Medpace (MEDP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changi ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 28th:Calix, Inc. (CALX) : This provider of cloud and software platforms, has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.Calix’s shares gained 35.9% over the last three months compared with the S&P 500’s advance of 14.9%. The company possesses a Momentum Score  of A.Medpace Holdings, Inc. (MEDP) : This clinical resea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 ______________ ...

主要为中小型生物技术公司提供临床研发外包服务的美国合同研究组织（CRO）Medpace刚刚公布的财报业绩强劲，股价大 涨。 EBITDA：二季度息税折旧摊销前利润（EBITDA）为1.305亿美元，同比增长16.2%，EBITDA利润率为21.6%，一 季度EBITDA同比增长2.6%、EBITDA利润率为21.2%。 2）业绩指引： 美东时间7月22日周二，Medpace股价（MEDP）跳空高开逾44%，早盘涨幅一度扩大到62.3%，后涨幅有所收窄，早盘尾声时 涨超50%，势将创收盘最高纪录，并创上市将近九年来最大单日涨幅。 Medpace股价暴涨也带飞了CRO概念股。周二美股早盘尾声时，Iqvia Holdings（IQV）涨近20%，ICLR PLC（ICLR）涨超 10%，Charles River Laboratories International（CRL）早盘曾涨超10%。 股价大涨前，本周一美股盘后，Medpace公布截至6月30日的公司第二季度财务业绩，并能提供以及2025年全年的业绩指引。 1）主要财务数据： 营收：二季度营收6.033亿美元，同比增长14.2%，分析师预期5.42亿美元， ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Medpace (MEDP) Q2 2025 Earnings Call July 22, 2025 09:00 AM ET Company ParticipantsLauren Morris - Director - IRAugust Troendle - Chairman & CEOJesse Geiger - PresidentKevin Brady - CFODave Windley - Managing DirectorJailendra Singh - Managing DirectorLuke Sergott - Director - Healthcare Equity ResearchCharles Rhyee - Managing DirectorKyle Crews - Equity Research AssociateConference Call ParticipantsAnn Hynes - MD & Senior Healthcare Services Equity AnalystMax Smock - Research Analyst - HealthcareMichael Ch ...

Medpace (MEDP) Q2 2025 Earnings Call July 22, 2025 09:00 AM ET Speaker0Good day ladies and gentlemen and welcome to the Medpace Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session. If you'd like to ask a question, please press 11 on your phone. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 again.As a reminder, this c ...

Financial Performance - Revenue for Q2 2025 was $603.3 million, a 14.2% increase compared to $528.1 million in Q2 2024 [13, 21] - Year-to-date revenue reached $1,161.9 million, an 11.8% increase from $1,039.1 million in 2024 [13, 21] - EBITDA for Q2 2025 was $130.5 million, a 16.2% increase compared to $112.3 million in Q2 2024 [21] - Year-to-date EBITDA reached $249.1 million, a 9.3% increase from $227.9 million in 2024 [21] - Net income for Q2 2025 was $90.3 million, a 2.2% increase compared to $88.4 million in Q2 2024 [21] - Net income per diluted share for Q2 2025 was $3.10, a 12.7% increase compared to $2.75 in Q2 2024 [21] Business Trends - Net new business awards for Q2 2025 were $620.5 million, a 12.6% increase compared to $551.0 million in Q2 2024 [13] - Ending backlog was $2,873.6 million, a 1.8% decrease compared to $2,924.9 million in Q2 2024 [13] Cash Flow - Free cash flow for Q2 2025 was $142.4 million, compared to $103.5 million in Q2 2024 [39, 41] - Free cash flow conversion was 109.2% for Q2 2025, compared to 92.2% in Q2 2024 [39, 41] Guidance - Full year 2025 revenue guidance is $2,420.0 million - $2,520.0 million, representing a 14.7% - 19.5% growth rate [28, 43] - Full year 2025 EBITDA guidance is $515.0 million - $545.0 million, representing a 7.3% - 13.5% growth rate [28, 43]

Medpace (MEDP) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to earnings of $2.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.33%. A quarter ago, it was expected that this provider of outsourced clinical development services would post earnings of $3.06 per share when it actually produced earnings of $3.67, delivering a surprise of +19.93%.Over th ...

Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 m.maley@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2025 Results CINCINNATI, OHIO, July 21, 2025-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue for the three months ended June 30, 2025 increased 14.2% to $603.3 m ...